Effects of monthly injected ibandronate on bone mineral density and microstructure in patients with primary osteoporosis after teriparatide treatment.

Not Applicable

• Conditions: Primary osteoporosis

• Registration Number: JPRN-UMIN000025799
• Lead Sponsor: agasaki University Hospital Department of Orthopaedic Surgery

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2017-01-26
• Study Completion: 2019-03-31
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: Female
• Target Recruitment: 66

Inclusion Criteria

Not provided

Exclusion Criteria

1Patients with a history of critical heart disease, hepatic disease, kidney disease, diabetes mellitus, cancer, endcrine disease, metabolic disease, and secondary osteoporosis. 2Patients taking steroids more than 5mg, and drugs affecting bone metabolism. 3Patients with a history of allergy to ibandronate or bisphosphonate and hypocalcemia. 4Patients with a history of Participation in clinical trials. 5More than 3 vertebral fractures between L1 toL4. 6Patients judged inappropriate by author.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Changing rates of bone mineral density from start to 12months after.

Secondary Outcome Measures

Name	Time	Method
1)Changing rates of bone mineral density of lumbar from start to 6 months after. 2)Areal bone mineral density of femur and distal radius,Changing rates of SOS in Calcaneus,Incidences of vertebral fracture,Meaturemenst of Bone turnover markers,Changing rates of Visual Analog Scale,Microarchitectures of cotical bone and cancellous bone,Changing rates of predictive bone stiffness,Changinn rates of femur morphology.